Taurolithocholic Acid Test

Most of what happens between your liver and your gut bacteria is invisible to routine labs. A standard liver panel measures enzymes leaking from damaged cells. A standard stool test counts microbes. Neither tells you what those microbes are actually doing to the molecules your liver sends downstream. TLCA (taurolithocholic acid) is one of those molecules, and its level reflects a conversation between your liver, your gut bacteria, and your immune system that no routine test captures.

This is a research-stage marker, so a single result will not deliver a diagnosis. What it can do is give you an early window into bile acid biology, which research has now linked to liver disease severity, gut inflammation, and neurological conditions. Used as part of a broader bile acid panel, it adds a layer of biological detail that ALT, AST, and total bile acids cannot.

What This Molecule Actually Is

Your liver makes bile acids from cholesterol and ships them through your digestive tract to help break down fat. Once those bile acids reach your intestine, gut bacteria modify them, producing what scientists call secondary bile acids. Lithocholic acid is one of those bacterial products. When your liver attaches a small molecule called taurine to it, you get taurolithocholic acid.

Beyond digestion, TLCA is a signaling molecule. It binds receptors on cells throughout your body, including a receptor called TGR5 (a docking site that triggers metabolic and hormonal responses). Through these receptors, bile acids like TLCA influence energy balance, blood sugar handling, immune signaling, and how strongly your gut walls fight inflammation.

Liver Disease Risk

Bile acid patterns shift early in liver disease, often before standard enzymes flag a problem. In metabolic dysfunction-associated steatotic liver disease (the new name for fatty liver disease), TLCA tends to rise alongside other taurine-conjugated bile acids as the disease progresses toward its more aggressive form, called MASH (a state where fatty liver has tipped into active inflammation and damage). The same pattern shows up in viral hepatitis and in the autoimmune liver disease primary biliary cholangitis, where elevated TLCA can also impair bile flow.

These findings come from research that mostly measured TLCA in blood, not stool. Whether fecal TLCA tracks the same liver disease patterns has been studied less directly. Still, the research consistently places TLCA among a small group of bile acids that change with liver disease severity in ways routine liver enzymes do not always catch.

Inflammatory Bowel Disease and Gut Inflammation

In ulcerative colitis, the picture flips. People with active UC tend to have lower fecal TLCA and lower levels of other secondary bile acids than healthy controls. The gut bacteria that normally convert primary bile acids into secondary forms get crowded out by the dysbiosis (the disrupted microbial balance) that comes with chronic inflammation.

Lower fecal TLCA in this setting is a sign that your microbial conversion machinery is depleted. Because secondary bile acids help calm gut inflammation through receptors on immune cells, less of them around can mean less of a brake on inflammation.

Reconciling the Two Patterns

TLCA appears to go up in liver disease and down in gut inflammation. That looks contradictory, but it is not. TLCA is not a simple good-or-bad number. It is a phenotype indicator that reflects two different breakdowns. When the liver is sick, conjugated bile acids back up into the bloodstream because the liver cannot move them efficiently. When the gut is inflamed, the bacteria that produce secondary bile acids in the colon die back, so fecal levels drop. The same molecule, two different stories. The right interpretation depends on which pattern you are looking at and which specimen the test uses.

Neurological Disease Signals

Bile acid signaling reaches the brain. In Parkinson's disease, higher TLCA along with related taurine-conjugated bile acids has been linked to worse motor symptom severity, while lower levels of a sulfated form of TLCA have been associated with Parkinson's incidence in general population samples. This evidence comes from research that measured TLCA in blood rather than stool, so the connection to fecal TLCA is indirect. The takeaway is not that TLCA causes Parkinson's, but that the bile acid system is one of several pathways through which gut microbes appear to interact with the brain.

Reference Ranges

There are no standardized clinical reference ranges for fecal TLCA. This is a research-stage marker, and labs that report it use analytical detection ranges rather than universally accepted clinical cutpoints. Different assays, different specimen handling, and different population baselines can all shift the absolute numbers. Treat any single result as an orientation point, not a verdict, and compare your results within the same lab over time for the most meaningful trend.

Research that has reported TLCA values typically presents them in very small concentration units or as percentages of total bile acids. The most useful interpretation is relative: how does your TLCA compare to your own previous values, and how does the broader pattern of primary versus secondary bile acids look on the same panel?

When Results Can Be Misleading

Bile acid concentrations are sensitive to recent activity, so a single reading can mislead you in several ways.

• Recent meals: bile acid release surges after eating, especially after fatty foods. Stool collected during a high-fat meal pattern can look very different from stool collected during a fasted or lower-fat period.
• Antibiotics: a recent course of antibiotics can dramatically reduce the bacteria that convert primary bile acids into secondary ones like TLCA. Levels can stay shifted for weeks after a course ends.
• Acute illness or diarrhea: rapid transit through the gut and inflammation in the colon both alter bile acid composition and can produce results that do not reflect your usual baseline.
• Specimen handling: bile acids can degrade if stool is not collected, stored, and shipped according to lab instructions. Inconsistent handling can shift values without anything changing in your body.

Tracking Your Trend

Because clinical cutpoints do not exist for fecal TLCA, your own trend over time is more informative than any single absolute number. A baseline gives you orientation. A retest after several months tells you whether your trajectory is moving and which direction it is heading. If you are making changes that affect your microbiome or your liver, retest in 3 to 6 months to see whether your bile acid profile is shifting. After that, an annual check is a reasonable cadence for ongoing tracking.

Look at TLCA in the context of the full bile acid panel rather than as a stand-alone number. The ratio of primary to secondary bile acids, the presence of sulfation, and the levels of related conjugated species like taurodeoxycholic acid all add useful context. Trends across the panel are often more interpretable than movement in any one molecule.

What to Do With an Abnormal Result

An out-of-range TLCA on its own is not actionable. What is actionable is the pattern. If your fecal TLCA is markedly low alongside low total secondary bile acids and you have gut symptoms, that pattern is worth investigating with a stool-based microbiome test and a clinical workup for inflammatory bowel disease. If you have liver risk factors and your bile acid profile shows a heavy shift toward conjugated species, a hepatology workup including a liver enzyme panel, imaging, and a discussion with a hepatologist is the appropriate next step. If your result is unexpected and you have no symptoms, retest after several weeks to confirm before drawing conclusions.